Johnson & Johnson (JNJ)

Close Price	Market Cap	P/E Ratio	Forward P/E Ratio	Implied Growth*	Implied Forward Growth*	Dividend	P/B Ratio
$186.57	$449.50B	18.0	17.6	10.2%	9.9%	$5.20 2.8%	5.7

Revenue & Net Income

	Date	Revenue	Net Income	EPS	Revenue Change	Net Income Change	EPS Change
0	2021-12-31	$78.7B	$20.9B	$7.93	N/A	N/A	N/A
1	2022-12-31	$80.0B	$17.9B	$6.86	1.6%	-14.1%	-13.5%
2	2023-12-31	$85.2B	$35.2B	$14.60	6.5%	95.9%	112.8%
3	2024-12-31	$88.8B	$14.1B	$5.84	4.3%	-60.0%	-60.0%
4	TTM 2025-03-31	$89.3B	$21.8B	$8.99	0.6%	55.1%	53.9%
5	Average				3.2%	19.2%	23.3%

EPS

Forecasts

Y/Y % Change

YoY Growth Rates

JNJ Year-over-Year Growth

	2021	2022	2023	2024	2025	2026	Average
Revenue Growth (%)		1.6%	6.5%	4.3%	5.4%	4.9%	4.5%
Revenue Analysts (#)	0	0	0	0	6	6
EPS Growth (%)		-14.1%	95.9%	-60.0%	86.0%	5.6%	22.7%
EPS Analysts (#)	0	0	0	0	7	7

Expenses

Year	Revenue ($)	Cost of Revenue ($)	R&D ($)	G&A ($)	SG&A ($)	Facilities / D&A ($)	Personnel ($)
2021	$78.7B	$16.0B	$14.3B	$20.1B	$20.1B	$7.4B	$-600.0M
2022	$80.0B	$17.6B	$14.1B	$20.2B	$20.2B	$7.0B	$-1.2B
2023	$85.2B	$19.1B	$15.1B	$20.1B	$20.1B	$7.5B	$-1.4B
2024	$88.8B	$20.1B	$17.2B	$22.0B	$22.0B	$7.3B	$-900.0M
TTM	$90.6B	$21.6B	$17.0B	$22.3B	$22.3B	$7.5B	$-600.0M

Year	Revenue Change (%)	Cost of Revenue Change (%)	R&D Change (%)	G&A Change (%)	SG&A Change (%)	Facilities / D&A Change (%)	Personnel Change (%)
2022	1.59	10.08	-0.99	0.64	0.64	-5.68	100.00
2023	6.46	8.18	6.72	-0.66	-0.66	7.40	16.67
2024	4.30	5.59	14.23	9.23	9.23	-1.96	-35.71
TTM	2.03	7.39	-1.40	1.65	1.65	1.61	-33.33

No unmapped expenses.

Segment Performance

axis1_JNJ_I_N_V_E_G_A_S_U_S_T_E_N_N_A_X_E_P_L_I_O_N_T_R_I_N_Z_A_T_R_E_V_I_C_T_A.png

axis1_JNJ_P_R_E_Z_I_S_T_A_P_R_E_Z_C_O_B_I_X_R_E_Z_O_L_S_T_A_S_Y_M_T_U_Z_A.png

SEGMENTS v2025-09-09 · 2025-11-10 08:23 UTC — Units: $B. Rows list fiscal years (last 3 + TTM) with revenue and operating income for each segment; the final row shows the TTM revenue mix (operating income columns display “—” where mix is not applicable).

Year	D A R Z A L E X Rev	D A R Z A L E X OI	Stelara Rev	Stelara OI	G E N E R A L Rev	G E N E R A L OI	A D V A N C E D Rev	A D V A N C E D OI	Tremfya Rev	Tremfya OI	I N V E G A S U S T E N N A X E P L I O N T R I N Z A T R E V I C T A Rev	I N V E G A S U S T E N N A X E P L I O N T R I N Z A T R E V I C T A OI	C O N T A C T L E N S E S O T H E R Rev	C O N T A C T L E N S E S O T H E R OI	T R A U M A Rev	T R A U M A OI	I M B R U V I C A Rev	I M B R U V I C A OI	E L E C T R O P H Y S I O L O G Y Rev	E L E C T R O P H Y S I O L O G Y OI	Xarelto Rev	Xarelto OI	Simponi Simponi Aria Rev	Simponi Simponi Aria OI	U P T R A V I Rev	U P T R A V I OI	E R L E A D A Rev	E R L E A D A OI	Remicade Rev	Remicade OI	P R E Z I S T A P R E Z C O B I X R E Z O L S T A S Y M T U Z A Rev	P R E Z I S T A P R E Z C O B I X R E Z O L S T A S Y M T U Z A OI	H I P S Rev	H I P S OI	K N E E S Rev	K N E E S OI	Erleada Rev	Erleada OI	S U R G I C A L Rev	S U R G I C A L OI	S P I N E S P O R T S O T H E R Rev	S P I N E S P O R T S O T H E R OI	C A R V Y K T I Rev	C A R V Y K T I OI	S P I N E O T H E R Rev	S P I N E O T H E R OI	E D U R A N Trilpivirine Rev	E D U R A N Trilpivirine OI	S P R A V A T O Rev	S P R A V A T O OI	Other Rev	Other OI	O P S U M I T O P S Y N V I Rev	O P S U M I T O P S Y N V I OI	O T H E R N E U R O S C I E N C E Rev	O T H E R N E U R O S C I E N C E OI	O P S U M I T Rev	O P S U M I T OI	Abiomed Rev	Abiomed OI	Other Oncology Rev	Other Oncology OI	C O N C E R T A Methylphenidate Rev	C O N C E R T A Methylphenidate OI	Z Y T I G A Rev	Z Y T I G A OI	R Y B R E V A N T L A Z C L U Z E Rev	R Y B R E V A N T L A Z C L U Z E OI	C A P L Y T A Rev	C A P L Y T A OI	Tecvayli Rev	Tecvayli OI	Shockwave Medical Inc. Rev	Shockwave Medical Inc. OI	T E C V A Y L I Rev	T E C V A Y L I OI	T A L V E Y Rev	T A L V E Y OI	Other Infectious Diseases Rev	Other Infectious Diseases OI	Other Cardiovascular Rev	Other Cardiovascular OI	Other Pulmonary Hypertension Rev	Other Pulmonary Hypertension OI	C O V I D19 Rev	C O V I D19 OI	Other Immunology Rev	Other Immunology OI	Total Rev	Total OI
2023	35.4B	0.00B	41.2B	0.00B	21B	0.00B	18.5B	0.00B	11.6B	0.00B	16.5B	0.00B	14.5B	0.00B	11.7B	0.00B	14.1B	0.00B	17.2B	0.00B	9.68B	0.00B	8.76B	0.00B	5.81B	0.00B	–	–	8.36B	0.00B	7.59B	0.00B	6.15B	0.00B	5.63B	0.00B	8.54B	0.00B	5.35B	0.00B	11.6B	0.00B	1.26B	0.00B	–	–	4.32B	0.00B	2.13B	0.00B	5.44B	0.00B	–	–	6.57B	0.00B	7.51B	0.00B	2.67B	0.00B	1.81B	0.00B	2.85B	0.00B	5.31B	0.00B	–	–	–	–	–	–	–	–	0.82B	0.00B	–	–	1.23B	0.00B	1.38B	0.00B	1.15B	0.00B	6.59B	0.00B	0.06B	0.00B	330.3B	0.00B
2024	23.3B	0.00B	20.7B	0.00B	10.7B	0.00B	8.98B	0.00B	7.34B	0.00B	8.44B	0.00B	7.47B	0.00B	6.10B	0.00B	6.08B	0.00B	10.5B	0.00B	4.75B	0.00B	4.38B	0.00B	3.63B	0.00B	–	–	3.21B	0.00B	3.42B	0.00B	3.28B	0.00B	3.09B	0.00B	6.00B	0.00B	2.83B	0.00B	5.85B	0.00B	1.93B	0.00B	–	–	2.54B	0.00B	2.15B	0.00B	2.38B	0.00B	–	–	2.35B	0.00B	4.37B	0.00B	2.99B	0.00B	1.86B	0.00B	1.28B	0.00B	1.26B	0.00B	–	–	–	–	–	–	1.13B	0.00B	1.10B	0.00B	–	–	0.43B	0.00B	0.76B	0.00B	0.56B	0.00B	0.40B	0.00B	0.01B	0.00B	177.6B	0.00B
TTM	51.6B	0.00B	33.6B	0.00B	21.7B	0.00B	18.1B	0.00B	17.3B	0.00B	16B	0.00B	15.3B	0.00B	12.3B	0.00B	11.7B	0.00B	10.5B	0.00B	9.91B	0.00B	9.82B	0.00B	7.42B	0.00B	7.10B	0.00B	6.96B	0.00B	6.61B	0.00B	6.56B	0.00B	6.15B	0.00B	6.00B	0.00B	5.88B	0.00B	5.85B	0.00B	5.64B	0.00B	5.59B	0.00B	5.52B	0.00B	5.46B	0.00B	5.12B	0.00B	4.52B	0.00B	4.47B	0.00B	4.37B	0.00B	2.99B	0.00B	2.60B	0.00B	2.47B	0.00B	2.25B	0.00B	1.43B	0.00B	1.38B	0.00B	1.34B	0.00B	1.13B	0.00B	1.10B	0.00B	0.87B	0.00B	0.79B	0.00B	0.76B	0.00B	0.56B	0.00B	0.40B	0.00B	0.07B	0.00B	347.2B	0.00B
% of Total (TTM)	14.9%	—	9.7%	—	6.2%	—	5.2%	—	5.0%	—	4.6%	—	4.4%	—	3.6%	—	3.4%	—	3.0%	—	2.9%	—	2.8%	—	2.1%	—	2.0%	—	2.0%	—	1.9%	—	1.9%	—	1.8%	—	1.7%	—	1.7%	—	1.7%	—	1.6%	—	1.6%	—	1.6%	—	1.6%	—	1.5%	—	1.3%	—	1.3%	—	1.3%	—	0.9%	—	0.7%	—	0.7%	—	0.6%	—	0.4%	—	0.4%	—	0.4%	—	0.3%	—	0.3%	—	0.3%	—	0.2%	—	0.2%	—	0.2%	—	0.1%	—	0.0%	—	100%	—

SEGMENTS v2025-09-09 · 2025-11-10 08:23 UTC — Units: $B. Rows list fiscal years (last 3 + TTM) with revenue and operating income for each segment; the final row shows the TTM revenue mix (operating income columns display “—” where mix is not applicable).

Year	Innovative Medicine Rev	Innovative Medicine OI	Med Tech Rev	Med Tech OI	Total Rev	Total OI
2023	536.6B	0.00B	289.1B	0.00B	825.7B	0.00B
2024	284.8B	0.00B	159.3B	0.00B	444.1B	0.00B
TTM	525.6B	0.00B	301.8B	0.00B	827.4B	0.00B
% of Total (TTM)	63.5%	—	36.5%	—	100%	—

Balance Sheet

	Metric	Value
0	Total Assets	$193,389M
1	Cash	$18,577M
2	Total Liabilities	$114,916M
3	Total Debt	$50,761M
4	Total Equity	$78,473M
5	Debt to Equity Ratio	0.65

EPS & Dividend

Valuation

Share Price	Treasury Yield	Estimates	Fair Value (P/E)	Fair Value (P/S)	Current P/S	Current P/E
$149.79	4.4%	Nicks Growth: N/A Nick's Expected Margin: N/A FINVIZ Growth: 6%	Nicks: 6 Finviz: 12	Nick's: 0.000	4.0	16.7

Basis	Year	Nicks Valuation	Nicks vs Share Price	Finviz Valuation	Finviz vs Share Price
$8.99 EPS	TTM	$57.47	-61.6%	$104.59	-30.2%
$10.60 EPS	2025	$67.77	-54.8%	$123.32	-17.7%
$10.98 EPS	2026	$70.20	-53.1%	$127.74	-14.7%

Implied Growth

	Average		Median		Std Dev		Current		Percentile
	TTM	Forward	TTM	Forward	TTM	Forward	TTM	Forward	TTM	Forward
Timeframe
1 Year	10.53%	9.32%	10.54%	9.38%	0.43%	0.62%	10.16%	9.91%	20.4%	78.7%
3 Years	10.53%	9.32%	10.54%	9.38%	0.43%	0.62%	10.16%	9.91%	20.4%	78.7%
5 Years	10.53%	9.32%	10.54%	9.38%	0.43%	0.62%	10.16%	9.91%	20.4%	78.7%
10 Years	10.53%	9.32%	10.54%	9.38%	0.43%	0.62%	10.16%	9.91%	20.4%	78.7%

Johnson & Johnson — JNJ